Summary
Boston Scientific Corporation reported first-quarter 2020 net sales of $2.543 billion, a slight increase of 2.0% year-over-year, driven by operational growth partially offset by foreign currency fluctuations. However, the company's net income significantly declined to $11 million ($0.01 per diluted share) from $424 million ($0.30 per diluted share) in the prior year. This substantial decrease in profitability was impacted by a $380 million after-tax charge, primarily related to amortization, intangible asset impairment, and other adjustments. The ongoing COVID-19 pandemic began to materially impact business trends in March 2020, leading to a significant decline in procedural volumes and consequently revenue and operating income, with expectations of a more severe impact in the second quarter. Management has implemented cost reduction initiatives and financial covenant amendments to navigate the uncertain environment. The company is actively managing its liquidity and capital resources. Despite the challenging near-term outlook due to COVID-19, Boston Scientific remains focused on its long-term fundamentals, driven by its innovative product portfolio and strategic growth initiatives. The company ended the quarter with $370 million in cash and cash equivalents and working capital of $848 million, while total debt stood at $10.336 billion. Investors should monitor the company's ability to manage through the pandemic's impact, particularly the extent of procedural deferrals and the pace of recovery, as well as the effectiveness of its cost-saving measures.
Financial Highlights
51 data points| Revenue | $2.54B |
| Cost of Revenue | $806.00M |
| Gross Profit | $1.74B |
| SG&A Expenses | $978.00M |
| Operating Expenses | $1.59B |
| Operating Income | $146.00M |
| Interest Expense | $88.00M |
| Net Income | $11.00M |
| EPS (Basic) | $0.01 |
| EPS (Diluted) | $0.01 |
| Shares Outstanding (Basic) | 1.40B |
| Shares Outstanding (Diluted) | 1.41B |
Key Highlights
- 1Net sales increased by 2.0% to $2.543 billion in Q1 2020, driven by operational growth, but negatively impacted by COVID-19 in March.
- 2Net income significantly decreased to $11 million ($0.01/share) from $424 million ($0.30/share) in Q1 2019, due to $380 million in after-tax charges.
- 3Adjusted net income (excluding certain charges) was $391 million ($0.28/share) in Q1 2020, down from $490 million ($0.35/share) in Q1 2019.
- 4Cash from operations was negative at $(77) million for Q1 2020, compared to $350 million in Q1 2019.
- 5The company ended the quarter with $370 million in cash and cash equivalents and total debt of $10.336 billion.
- 6Significant intangible asset impairment charges of $198 million were recorded in Q1 2020, compared to $67 million in Q1 2019.
- 7The company is proactively managing the impact of the COVID-19 pandemic through cost-saving measures and amended financial covenants on its credit facilities.